ABBVIE-CARO URO-ONCOLOGIC RADIATION AWARDS

2022 Award recipients

Morales, Brandon

DNA repair gene polymorphisms associated with tumour control and treatment toxicity in prostate cancer patients treated with prostate HDR brachytherapy.

Menard, Cynthia

Ablative radiotherapy to consolidate systemic response in metastatic prostate cancer (AnChoR-Prostate).

Winter, Jeff

Biological MR-guided adaptive prostate radiation therapy on the MR-Linac.

Berlin, Alejandro

The influence of disease labeling on perceptions and treatment decisions for indolent prostate cancer.

Navarro, Inmaculada

Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas in salvage radiotherapy for prostate cancer.

www.caro-acro.ca



of Collaboration, Research and Care

In 2001, AbbVie and the Canadian Association of Radiation Oncology (CARO) joined forces and founded the AbbVie-CARO Uro-Oncologic Radiation Award (ACURA) program. Over the past 22 years, the ACURA program has donated 3.5 million dollars to support more than 160 projects designed to advance prostate cancer treatments.

"The long-standing and generous support from AbbVie makes it possible for the ACURA program to fund Canadian Radiation Oncologists in investigating novel approaches to the diagnosis and care of patients with prostate cancer, and to improve their lives throughout the cancer journey."

Dr. Harvey Quon, ACURA Advisory Group Chair

"For 22 years, AbbVie has proudly supported Canadian radiation oncology clinicians and researchers who work tirelessly to innovate to advance prostate cancer care. Congratulations to our 2022 ACURA recipients and thank you to ACURA for all that you do to make a remarkable impact on the lives of patients."

Tracey Ramsay, Vice President and General Manager, AbbVie Canada



© AbbVie Corporation CA-LUPR-220030A – July 2022





